Thymosin α-1 vs LL-37.

Thymosin alpha-1 (Tα1, international nonproprietary name thymalfasin; brand name Zadaxin) is a synthetic 28-amino-acid acetylated peptide identical to a naturally occurring fragment derived from prothymosin alpha, a protein produced in the thymus. It belongs to the thymosin family of thymic-derived peptides and is one of the most clinically studied immunomodulatory peptides, marketed as a prescription immune modulator in numerous countries outside the United States.

LL-37 is the only human cathelicidin-derived antimicrobial peptide, a 37-residue cationic, amphipathic alpha-helical peptide (named for its two leading leucine residues) cleaved from the C-terminus of the precursor protein hCAP18 (gene CAMP). It is an endogenous component of innate immunity, produced by neutrophils, epithelial cells, keratinocytes, and other tissues, where it acts as both a broad-spectrum antimicrobial and a host-defense signaling molecule.

Tα1 is an immune modulator rather than a simple immune stimulant: it acts largely through Toll-like receptors, principally TLR2 and TLR9, on dendritic cells, monocytes/macrophages, and other antigen-presenting cells. Downstream MyD88-dependent signaling promotes dendritic cell maturation, biases naive T cells toward Th1 differentiation, augments natural killer cell and cytotoxic T-cell activity, and can modulate regulatory pathways including indoleamine 2,3-dioxygenase. In settings of immune exhaustion or sepsis-associated immunoparalysis, the proposed benefit is restoration of T-lymphocyte numbers and function (e.g., raising depleted CD4+/CD8+ counts and reducing markers of T-cell exhaustion) rather than broad immune activation.

As a cationic amphipathic peptide, LL-37 binds anionic microbial membranes and disrupts them (a detergent-like/toroidal-pore mechanism), giving broad activity against Gram-positive and Gram-negative bacteria, some fungi, and enveloped viruses, plus the ability to neutralize LPS and disrupt biofilms. Beyond direct killing, it is strongly immunomodulatory: it is chemotactic for neutrophils, monocytes, and T cells (acting partly via the FPR2/FPRL1 receptor), promotes angiogenesis and keratinocyte migration and proliferation (relevant to wound re-epithelialization), and modulates Toll-like-receptor and inflammatory signaling. A double-edged feature is that LL-37 can bind self-DNA/RNA and convert it into a potent activator of plasmacytoid dendritic cells via TLR9/TLR7, a pathway implicated in psoriasis and other autoimmunity.

Human evidence is most developed in chronic hepatitis B and as an adjunct in sepsis, but is mixed and often comes from China-based studies of variable quality. The largest dedicated sepsis trial, ETASS (Wu et al., Critical Care 2013, a multicenter single-blind RCT of 361 patients with severe sepsis), found a reduction in 28-day all-cause mortality that did not reach statistical significance, so its primary endpoint was formally negative; subsequent systematic reviews (e.g., Liu et al., BMC Infect Dis 2016) noted possible mortality benefit but flagged small sample sizes, heterogeneity, and risk of bias. In COVID-19, the widely cited Liu et al. (Clin Infect Dis 2020) report associating Tα1 with lower mortality was a retrospective review of only 76 severe cases, not a randomized trial, and cannot establish efficacy. For hepatitis B, meta-analyses (e.g., entecavir plus Tα1 in HBV-related cirrhosis, BMC Gastroenterol 2020) suggest possible adjunctive benefit on virologic and immune endpoints but again rest on heterogeneous trials; high-quality Western regulatory trials have not confirmed a clear benefit. Much of the broader "immune-restoring" and anti-cancer rationale remains preclinical or mechanistic.

Direct human interventional evidence is limited and centers on chronic wounds. A multicentric, prospective, randomized, placebo-controlled trial evaluated topical LL-37 in hard-to-heal venous leg ulcers (Gronberg et al., Wound Repair Regen, 2021, PMID 34687253), building on an earlier safety/efficacy study reporting improved healing of venous leg ulcers (PMID 25041740); these are small, wound-specific studies rather than large confirmatory trials. The great majority of the LL-37 literature is mechanistic, in vitro, or animal-based: for example, cathelicidin's protective role against urinary-tract infection was shown in mice and human cells (Chromek et al., Nat Med, 2006, PMID 16751768). Much of the peptide's purported breadth (antiviral, anticancer, antibiofilm, metabolic effects) remains preclinical, and endogenous LL-37 biology should not be conflated with proven benefit from administering exogenous LL-37 in humans. Honest summary: human efficacy data exist mainly for topical chronic-wound healing and remain early-stage; systemic therapeutic use is not established.

Across decades of clinical use as thymalfasin, Tα1 has generally been reported as well tolerated, with injection-site reactions among the more commonly noted effects; it is a peptide given by injection in studied settings. Because its action is immunomodulatory, theoretical and context-dependent concerns include effects in autoimmune disease, transplant recipients, or other immune-sensitive populations, and immunogenicity is one reason regulators have scrutinized compounded versions. Importantly, much safety data comes from regulated pharmaceutical product used under medical supervision; the purity, identity, and safety of research-grade or compounded "gray market" material are not assured, and long-term safety outside approved indications is not well characterized.

LL-37 has a genuinely double-edged profile: the same self-nucleic-acid-binding and dendritic-cell-activating activity that aids host defense is mechanistically implicated in autoimmune and inflammatory disease, and LL-37 is recognized as an autoantigen targeted by T cells in psoriasis. Elevated or dysregulated cathelicidin has also been linked to rosacea, lupus, atherosclerosis, and a context-dependent (pro- or anti-) role in cancer, so effects are highly tissue- and concentration-dependent. At higher concentrations the peptide can be cytotoxic and hemolytic to host cells, and it can be degraded or inactivated by serum and proteases, complicating systemic delivery. Human safety data are essentially confined to localized topical wound use; the safety of exogenous systemic administration in humans is not established.

Thymalfasin (Zadaxin) is approved and marketed as a prescription drug in roughly 30-plus countries (including China, Italy, and parts of Asia, Latin America, and the Middle East), chiefly for chronic hepatitis B and as an immune adjunct, but it is NOT approved by the US FDA or centrally by the EMA; in the US it has held orphan-drug designations and been studied investigationally. In US compounding, FDA placed thymosin alpha-1 in Category 2 of the interim 503A bulk substances list in 2023 (citing safety/data concerns), and in 2024 it was removed from Category 2 after its nomination was withdrawn, leaving it without a clear compounding pathway.

LL-37 is not an FDA-approved drug; it is an endogenous human peptide studied as an investigational and research-use agent. Clinical work has been early-phase and indication-specific (notably topical chronic-wound trials), and no LL-37 product holds general marketing approval.